Overview

PET Imaging of Vaso-Occlusive (VOC) in SCD

Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to find objective biomarkers of vaso-occlusion (blood vessel blockage) in people with SCD. Using information from earlier studies and work being done, researchers have developed a strategy to image VOC, using positron emission tomography (PET). The ability to see and measure VOC in SCD patients can help patient care, by showing when and how a VOC is occurring or going to occur. Studying this method will also help in future drug research, as it will allow researchers to deliver promising new medications that target hyper-adhesion and sickling in people with SCD.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Enrico M Novelli
Collaborator:
The Pittsburgh Foundation
Criteria
Inclusion Criteria:

- Have a confirmed diagnosis of SCD (HbSS, SC, S/β-thalassemia, SD, SE, SO) by
hemoglobin electrophoresis/High Performance Liquid Chromatography (HPLC)

- Aged 18 and above

- Ability to understand and provide informed consent.

- If receiving hydroxyurea or L-glutamine, crizanlizumab, voxelotor or erythropoietin
stimulating agents, must have been receiving the drug for at least 12 weeks prior to
screening and plan to continue taking the drug at the same dose and schedule during
the study

- Experienced at least 2 VOCs leading to healthcare visit within the 12 months prior to
screening visit as determined by medical history.

Exclusion Criteria:

- Active malignancy

- Current pregnancy or breast feeding

- Participating in a chronic transfusion program (pre-planned series of transfusions for
prophylactic purposes) and/or planning on undergoing an exchange transfusion during
the duration of the study; episodic transfusion in response to worsened anemia or VOC
is permitted

- Received active treatment on another investigational trial within 30 days (or 5
half-lives of that agent, whichever is greater) prior to screening visit or plans to
participate in another investigational drug trial